Breiter Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Breiter Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,675	Closed	-$377K	–	125
2020 Q4	$377K	Hold	2,675	–	–	0.26%	87
2020 Q3	$298K	Hold	2,675	–	–	0.24%	84
2020 Q2	$299K	Hold	2,675	–	–	0.28%	81
2020 Q1	$207K	Buy	+2,675	New	+$237K	0.24%	92

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Breiter Capital Management's XBI Position: Q1 2021 in Review

Breiter Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2021, closing a stake of 2,675 shares — an estimated $377K sold.

Breiter Capital Management first reported a position in XBI in Q1 2020 and held it in 4 quarters. The position peaked at $377K in Q4 2020. 644 funds tracked by Wall St. Rank hold XBI as of Q1 2021.

Breiter Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2021 after selling out during the quarter.
Breiter Capital Management sold 2,675 State Street SPDR S&P Biotech ETF shares in Q1 2021, an estimated $377K.
Breiter Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and held it in 4 quarters.
Breiter Capital Management's State Street SPDR S&P Biotech ETF position peaked at $377K in Q4 2020.
644 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2021.

Based on Breiter Capital Management's 13F filing for Q1 2021, filed 13 Apr 2021.